Your health
At Pharming we strive to develop outstanding therapies for a range of medical needs based on our unique science and technology. We specialize in the production of human proteins with healthcare potential, highly pure and in large quantities. Healthcare applications vary from treatment of genetic disorders, to repair of tissue damage during surgery and beyond.

Our focus
Pharming today focuses its research and development efforts on a limited number of therapeutic applications with high value and significant market potential. Our most advanced product is aimed at the treatment of a serious genetic disease called hereditary angioedema (HAE).

Powered by science
Pharming's proteins are produced using its innovative technology and isolated from milk of transgenic cows or rabbits. These transgenic animals are identical to non-transgenic members of the same species, but have an extra gene built in that makes them produce specific human proteins in their milk. The simple and elegant method yields the exact human protein in high quantities. In addition, the method enables for easy purification and formulation of the protein product, which makes it suitable for medical manufacturing and application.

People and sites
Pharming Group NV has approximately 90 people working in three different locations in the Netherlands and the USA. More than 80 percent of them are employed in R&D and operations. The company’s headquarters are in Leiden. Subsidiaries are Pharming Healthcare Inc in Wisconsin, US and the Broekman Institute in the Netherlands.

Portfolio
Pharming's most advanced product is Rhucin® for the treatment of Hereditary Angioedema. The Company is preparing its regulatory submission for the EU and the USA. Pharming is also planning to develop its active component, recombinant human C1 inhibitor, for other indications than HAE. Recombinant human lactoferrin (hLF) - with potential for the treatment of infections and inflammatory diseases - has successfully passed phase I clinical trials. Pharming has filed for Generally Recognized as Safe (GRAS) status with the FDA for nutritional applications. Additional recombinant products include a tissue sealant (rTS) and recombinant human fibrinogen (rhFIB) and recombinant human collagen type I (rhCOL) for intermediate products of medical and aesthetic applications.

Prodarsan®, which is developped using the DNage technology, is being tested in a phase I study for prevention of premature ageing. Other DNage products for ageing diseases and NovaThera combination products for tissue repair purposes are in research phase.